(Q43935588)

28 November 2017

0 references

CMV prophylaxis: what is valid in 2002? (English)

1 reference

28 November 2017

Uwe Heemann

1

1 reference

28 November 2017

Rene R Wenzel

series ordinal

2

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Nephrology Dialysis Transplantation

28 November 2017

published in

1 reference

28 November 2017

volume

17

1 reference

28 November 2017

issue

4

1 reference

28 November 2017

page(s)

556-559

1 reference

Late-acute renal allograft rejection and symptomless cytomegalovirus infection

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Cytomegalovirus infection and graft rejection in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F17.4.556

21 January 2018

Identifiers

DOI

10.1093/NDT/17.4.556

1 reference

28 November 2017

1 reference